Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public...
Constellation Pharmaceuticals ( CNST +17.4% ) is up on double normal volume on the heels of updated interim data from an open-label Phase 2 clinical trial, MANIFEST , evaluating co-lead candidate CPI-0610, with and without ruxolitinib, in myelofibrosis (MF) patients. The results were pr...
Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610 In the first-line treatment arm, 12 out of 15 (80%) evaluable JAK-inhibitor-naïve patients treated with a CPI-0610 / ruxolitinib combi...
Constellation Pharmaceuticals ( CNST ) released positive preliminary results from its phase 2 study using CPI-0610 as a second-line therapy for patients with myelofibrosis. These results prove that the drug works in treating this patient population, but more important than that, it shows tha...
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor event and webcast on Dece...
Written by Daniel Cohen and Scott Matusow Karuna Therapeutics (KRTX), NextCure (NXTC), and Constellation Pharmaceuticals (CNST) are but the latest examples of how the biotech sector has been heating up. All 3 of these names have seen very strong stock appreciation on earl...
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present ...
This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...
November 7, 2019 Palm Beach, FL – November 7, 2019 – Researchers in nanomedicine are making some big-time advances according to reports in various industry journals. Nanomedicine, a relatively new but rapidly developing branch of nanotechnology (the study, development an...
Stocks finished Wednesday's session close to where they started, with major market benchmarks getting pushed and pulled by conflicting readings on the health of the U.S. economy and the 10-year-old bull market. Investors seem to be waiting for some positive catalyst to send indexes further into ...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...